Current status of antibody therapy for breast cancer

Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in prima...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2004-01, Vol.11 (1), p.10-14
Hauptverfasser:	Toi, Masakazu, Takada, Masahiro, Bando, Hiroko, Toyama, Kazumi, Yamashiro, Hiroyasu, Horiguchi, Shinichiro, Saji, Shigehira
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Clinical Trials as Topic Female Genes, erbB-2 - genetics Humans Neoplasm Metastasis Receptor, ErbB-2 - drug effects Receptor, ErbB-2 - genetics Trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in primary tumors. The impact of this therapy might be as great as that of endocrine therapy from a historical point of view. A number of new approaches using trastuzumab for seeking individualized treatment are being tested in current clinical trials. We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer.
ISSN:	1340-6868 1880-4233
DOI:	10.1007/BF02967994